mAb Pipeline Candidates

About Zoetis

Zoetis is the global leader in animal health, with a $50.57B market valuation and 2024 revenue of $9.3B. The company operates a diversified, two-segment model (Livestock and Companion Animal) and is distinguished by its deep R&D pipeline and commercial scale. Its strategy is centered on a 'Continuum of Care' approach—predicting, preventing, detecting, and treating disease—supported by significant investments in monoclonal antibodies, diagnostics, and digital technologies to drive durable growth.

Therapeutic Areas